[ad_1]
“European science works!” Said the president of the European Commission, Ursula von der Leyen, congratulating the US pharmaceutical giant Pfizer and the German company BioNTech for a breakthrough in testing the new vaccine.
The European Medicines Agency (EMA) has said it has not yet received clinical trial data from Pfizer to approve the vaccine, which manufacturers say is 90 percent effective.
However, Brussels has already set aside funds to reserve tens of millions of vaccine doses for various companies and intends to turn its pre-agreement with Pfizer and BioNTech into a contract.
Von der Leyen wrote on Twitter that the European Commission “would soon sign a contract with them for up to 300 million euros.” dose ”.
However, in response to the different levels of quarantine announced in many EU countries by the COVID-19 pandemic, von der Leyen warned: “For now, let’s continue to protect each other.”
EU Health Commissioner Stela Kiriakides said the companies were “encouraging”, adding: “We will do everything possible to ensure that vaccines are safe and effective.”
Earlier, officials said Brussels would likely still take until next year to authorize distribution of the vaccines, although it had sped up the approval process.
[ad_2]
